Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216343
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanz Casañas, Roser-
dc.contributor.authorClares Naveros, Beatriz-
dc.contributor.authorMallandrich Miret, Mireia-
dc.contributor.authorSuñer Carbó, J. (Joaquim)-
dc.contributor.authorMontes López, María Jesús-
dc.contributor.authorCalpena Campmany, Ana-
dc.date.accessioned2024-11-11T12:38:35Z-
dc.date.available2024-11-11T12:38:35Z-
dc.date.issued2017-11-13-
dc.identifier.issn0378-5173-
dc.identifier.urihttps://hdl.handle.net/2445/216343-
dc.description.abstractThe main purpose of this study was to develop a semisolid mucoadhesive formulation for the non-invasive vaginal administration of doxepin (DOX) for relief of pain derived from the scarring process after surgery. An orafix® platform loading DOX was tested for adequate stability, rheology and vaginal mucoadhesion capacity. The formulation exhibited appropriate pH and was microbiologically stable. The rheological studies confirmed its pseudoplastic and thixotropic nature with prevalence of the elastic behavior component over the viscous one. Appropriate syringeability and spreadability results were also confirmed. Different experiments showed adequate mucoadhesion capacity even in the presence of simulated vaginal fluid. Finally, DOX release, permeation and retention in vaginal mucosa studies were also accomplished with promising results. DOX release kinetics followed the modified Higuchi model and the permeation studies did not render such high values as to suggest potential systemic absorption which could lead to undesirable systemic side effects. Therefore, we can hypostatize that the proposed formulation may assist to fill in the therapeutic gap regarding pure pain relief at local level in vagina.-
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ijpharm.2017.11.027-
dc.relation.ispartofInternational Journal of Pharmaceutics, 2017, vol. 535, p. 393-401-
dc.relation.urihttps://doi.org/10.1016/j.ijpharm.2017.11.027-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationMalalties de la vagina-
dc.subject.classificationCandidiasi-
dc.subject.classificationMalalties de l'aparell genital femení-
dc.subject.otherVagina diseases-
dc.subject.otherCandidiasis-
dc.subject.otherFemale reproductive system diseases-
dc.titleDevelopment of a mucoadhesive delivery system for control release of doxepin with application in vaginal pain relief assciated with gynecological surgery.-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec678106-
dc.date.updated2024-11-11T12:38:35Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
207441.pdf617.32 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons